Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan

Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them.

So, what is the potential for these game-changing GLP-1 products now that Novo’s Wegovy is showing it can help boost heart health?